Today’s finance is challenging in the medical environment. Cost seems to be of central concern to decision makers. This could lead you to wonder if research and development can flourish. To develop a new medication is costly and the payoff might appear in jeopardy to those that invest. Recently a new ground breaking drug called Sugammadex has been approved for use in over 40 countries around the world but further delayed in the U.S.
Sugammadex is a SRBA (Selective Relaxant Binding Agent) and the first developed that can quickly reverse a profound neuromuscular block. Current drugs used today like Neostigmine have undesired autonomic effects like bradycardia which then needs to be countered with Robinul. Sugammadex encapsulates Rocuronium and Vecuronium and allows for less residual neuro blocking effects on the patient. There are many side affects to non-steroidal drugs like Succinylcholine. With the use of a drug like Sugammadex , Rocuronium would become a drug that would have a faster onset and a shorter duration. One drug could change the scope of practice in a profound way.
On July 29th 2008 Sugammadex was approved in the E.U. and in August of the same year the F.D.A rejected the drug out of concerns about patient allergic reactions. Five years have now passed and much more research available. In July the F.D.A. cancelled a review board scheduled with the drug maker, needing more time to assess the results of an inspection to a clinical site.
The development of new drugs in the field of Anesthesia has got to be the most important way of advancing the profession. Cost to benefit ratios can be dissected to discover whether the affects of a ground breaking drug on a patient outcome are worth the extra cost of the new drug. The field of Anesthesia must rely on research and development to move forward and a drug like Sugammadex is meeting quite a bit of resistance. Hopefully this does not discourage other drug innovators.
Please join StudyMode to read the full document